Does the future of science lie in 'bioconvergence'?
The concept of 'bioconvergence' brings together experts, processes, and technologies across biotech, software, and engineering, to meet today's challenges.
Belén Garijo is the Chair of the Executive Board and CEO of Merck. She joined Merck in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015. Before taking her current office in May 2021, Belén Garijo served as Vice-Chair of the Executive Board and Deputy CEO.
Before joining Merck, Belén Garijo served as the Senior Vice President Global Operations Europe at Sanofi-Aventis, where she was also a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, subsequently leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003, she served as Global Vice President Oncology at Aventis and from 1996 as Director of the Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer.
Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA.
The concept of 'bioconvergence' brings together experts, processes, and technologies across biotech, software, and engineering, to meet today's challenges.
Digital health: The integration of data, biotech and digital technologies into services is transforming the way healthcare stakeholders approach research and patient care
Schistosomiasis, also known as bilharzia, is a neglected tropical disease that kills 200,000 of the world's poorest each year. Here's how to eliminate it.
The work of inaugural Johann Anton Merck award winner Professor Caroline Dive is making testing for cancer simpler and more accessible to more patients.
新型コロナウイルスの大流行により介護の必要性が増し、予期せぬ大きな課題が提起される中、介護者を認識し、評価し、性差による偏向を減らしていくことの緊急性が高まっています。特に、リソースが限られ、患者の多くが入院できない状況において、新型コロナウイルスの患者とその家族にとって、緩和ケアおよび終末期ケアは必要性の高いものとなると考えられます。
This crisis presents an opportunity to develop new policies and implement flexible working for carers to promote gender equality in the home and workplace.
From the use of artificial intelligence in drug development to innovations in clinical trials, innovation is on the horizon.
Closing the gender pay gap is a necessary goal in itself - but research shows that companies with a greater number of women in leadership outperform their peers
Looking at disease on a molecular level is driving the trend towards treatment tailored to the individual patient.